MX428218B - Compuesto triciclico fusionado y uso farmaceutico del mismo - Google Patents
Compuesto triciclico fusionado y uso farmaceutico del mismoInfo
- Publication number
- MX428218B MX428218B MX2022010950A MX2022010950A MX428218B MX 428218 B MX428218 B MX 428218B MX 2022010950 A MX2022010950 A MX 2022010950A MX 2022010950 A MX2022010950 A MX 2022010950A MX 428218 B MX428218 B MX 428218B
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- disease
- heart failure
- retinopathy
- diabetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11002—[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
Abstract
La presente invención proporciona un compuesto que tiene un inhibidor de actividad de PDHK y útil para el tratamiento o profilaxis de diabetes (diabetes tipo 1, diabetes tipo 2 etc.), síndrome de resistencia a la insulina, síndrome metabólico, hiperglucemia, hiperlactacidemia, complicación diabéticas (neuropatía diabética, retinopatía diabética, nefropatía diabética, catarata etc.), insuficiencia cardíaca (insuficiencia cardíaca aguda, insuficiencia cardíaca crónica), miocardiopatía, isquemia de miocardio, infarto de miocardio, angina de pecho, dislipidemia, aterosclerosis, enfermedad de las arterias periféricas, claudicación intermitente, enfermedad pulmonar obstructiva crónica s, isquemia cerebral, apoplejía cerebral, enfermedad mitocondrial, encefalomiopatía mitocondrial, cáncer, hipertensión pulmonar, enfermedad de Alzheimer, demencia vascular, glaucoma, retinopatía diabética, retinopatía del prematuro, oclusión de la vena retiniana, neuropatía óptica isquémica o enfermedad renal crónica. La presente invención se refiere a un compuesto de la fórmula [I-a], o una de sus sales farmacéuticamente aceptables: (ver Fórmula) en donde cada símbolo es como se define en la DESCRIPCIÓN.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036931 | 2020-03-04 | ||
| JP2021001452 | 2021-01-07 | ||
| PCT/JP2021/008055 WO2021177330A1 (ja) | 2020-03-04 | 2021-03-03 | 縮合三環性化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2022010950A MX2022010950A (es) | 2022-10-07 |
| MX428218B true MX428218B (es) | 2025-11-13 |
Family
ID=77613417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010950A MX428218B (es) | 2020-03-04 | 2021-03-03 | Compuesto triciclico fusionado y uso farmaceutico del mismo |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230025880A1 (es) |
| EP (2) | EP4663189A3 (es) |
| JP (2) | JP7739012B2 (es) |
| KR (1) | KR20220149688A (es) |
| CN (1) | CN115151543B (es) |
| AU (1) | AU2021230880B2 (es) |
| BR (1) | BR112022014749A2 (es) |
| CA (1) | CA3166747A1 (es) |
| CL (1) | CL2022002355A1 (es) |
| CO (1) | CO2022012548A2 (es) |
| DK (1) | DK4116301T3 (es) |
| ES (1) | ES3052010T3 (es) |
| FI (1) | FI4116301T3 (es) |
| HR (1) | HRP20251364T1 (es) |
| IL (1) | IL295836B2 (es) |
| LT (1) | LT4116301T (es) |
| MX (1) | MX428218B (es) |
| PE (1) | PE20221908A1 (es) |
| PH (1) | PH12022552259A1 (es) |
| PL (1) | PL4116301T3 (es) |
| PT (1) | PT4116301T (es) |
| RS (1) | RS67408B1 (es) |
| SI (1) | SI4116301T1 (es) |
| SM (1) | SMT202500464T1 (es) |
| TW (1) | TWI884224B (es) |
| WO (1) | WO2021177330A1 (es) |
| ZA (1) | ZA202209620B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211273A1 (es) * | 2018-02-01 | 2021-07-19 | Japan Tobacco Inc | Compuesto de amida heterociclica nitrogenada y su uso para fines medicos |
| WO2023032940A1 (ja) * | 2021-09-01 | 2023-03-09 | 日本たばこ産業株式会社 | 含窒素三環性化合物及びその医薬用途 |
| BR112022014749A2 (pt) * | 2020-03-04 | 2022-10-11 | Japan Tobacco Inc | Composto tricíclico fundido e uso medicinal do mesmo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455547T1 (de) * | 2003-04-11 | 2010-02-15 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| KR100808551B1 (ko) * | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| TWI633885B (zh) * | 2013-03-15 | 2018-09-01 | 日商日本煙草產業股份有限公司 | 吡唑－醯胺化合物及其醫藥用途 |
| CA2994027C (en) * | 2015-07-31 | 2023-10-10 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| PE20211273A1 (es) * | 2018-02-01 | 2021-07-19 | Japan Tobacco Inc | Compuesto de amida heterociclica nitrogenada y su uso para fines medicos |
| EP3851103A4 (en) | 2018-09-11 | 2022-06-08 | Japan Tobacco Inc. | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND |
| BR112022014749A2 (pt) * | 2020-03-04 | 2022-10-11 | Japan Tobacco Inc | Composto tricíclico fundido e uso medicinal do mesmo |
-
2021
- 2021-03-03 BR BR112022014749A patent/BR112022014749A2/pt unknown
- 2021-03-03 KR KR1020227032125A patent/KR20220149688A/ko active Pending
- 2021-03-03 FI FIEP21764169.5T patent/FI4116301T3/fi active
- 2021-03-03 PH PH1/2022/552259A patent/PH12022552259A1/en unknown
- 2021-03-03 JP JP2021033150A patent/JP7739012B2/ja active Active
- 2021-03-03 PT PT217641695T patent/PT4116301T/pt unknown
- 2021-03-03 TW TW110107548A patent/TWI884224B/zh active
- 2021-03-03 SM SM20250464T patent/SMT202500464T1/it unknown
- 2021-03-03 HR HRP20251364TT patent/HRP20251364T1/hr unknown
- 2021-03-03 ES ES21764169T patent/ES3052010T3/es active Active
- 2021-03-03 AU AU2021230880A patent/AU2021230880B2/en active Active
- 2021-03-03 CA CA3166747A patent/CA3166747A1/en active Pending
- 2021-03-03 LT LTEPPCT/JP2021/008055T patent/LT4116301T/lt unknown
- 2021-03-03 WO PCT/JP2021/008055 patent/WO2021177330A1/ja not_active Ceased
- 2021-03-03 MX MX2022010950A patent/MX428218B/es unknown
- 2021-03-03 DK DK21764169.5T patent/DK4116301T3/da active
- 2021-03-03 EP EP25206111.4A patent/EP4663189A3/en active Pending
- 2021-03-03 PE PE2022001891A patent/PE20221908A1/es unknown
- 2021-03-03 CN CN202180018517.1A patent/CN115151543B/zh active Active
- 2021-03-03 IL IL295836A patent/IL295836B2/en unknown
- 2021-03-03 US US17/602,103 patent/US20230025880A1/en active Pending
- 2021-03-03 PL PL21764169.5T patent/PL4116301T3/pl unknown
- 2021-03-03 SI SI202130359T patent/SI4116301T1/sl unknown
- 2021-03-03 RS RS20251131A patent/RS67408B1/sr unknown
- 2021-03-03 EP EP21764169.5A patent/EP4116301B1/en active Active
-
2022
- 2022-08-29 CL CL2022002355A patent/CL2022002355A1/es unknown
- 2022-08-29 ZA ZA2022/09620A patent/ZA202209620B/en unknown
- 2022-09-01 CO CONC2022/0012548A patent/CO2022012548A2/es unknown
-
2025
- 2025-09-03 JP JP2025145992A patent/JP2025175000A/ja not_active Withdrawn